证券代码：301602 证券简称：超研股份 公告编号：2025-044 汕头市超声仪器研究所股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、会议召开时间： （1）现场会议：2025年9月15日（星期一）15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为2025 年9月15日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为2025年9月15日9:15-15:00期间的任意时间。 2、现场会议召开地点：广东省汕头市金砂路77号汕头市超声仪器研究所股 份有限公司1楼会议室。 3、召开方式：本次股东会采取现场投票与网络投票相结合的表决方式。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一） 召开情况 4、召集人：汕头市超声仪器研究所股份有限公司董事会 5、主持人：董事长李德来先生 6、会议的召开符合相关法律、行政法规、部门规章、规范性文件和公司 ...

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant focus on the pet economy and smart medical technology [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%. The net profit attributable to the parent company was 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% [8]. Market Position and Trends - The company participated in the 97th WVC annual meeting, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2]. - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [2]. Stock Performance - On September 9, the company's stock price fell by 1.93%, with a trading volume of 71.26 million yuan and a turnover rate of 4.80%, resulting in a total market capitalization of 10.871 billion yuan [1].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is experiencing growth in the pet economy and smart medical sectors, benefiting from the depreciation of the RMB and being a newly listed stock under the registration system [2]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [3][7]. - The company was established on November 15, 1982, and was listed on January 22, 2025 [3][7]. - The main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, with an average of 2,456 circulating shares per person, an increase of 19.98% [8]. Market Position and Trends - The company participated in the 97th WVC annual conference, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and engaging with industry experts [2]. - The company’s overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [2]. Shareholder Composition - As of June 30, 2025, the largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.9127 million shares, followed by Southern Zhongzheng 1000 ETF with 514,500 shares [9].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant focus on the pet economy and smart medical technology [2][3][7]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the first half of 2025, the company achieved a revenue of 184 million yuan, representing a year-on-year growth of 15.00%. The net profit attributable to the parent company was 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% [8]. Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. - The company is involved in various concept sectors, including nuclear power, medical devices, smart healthcare, and newly listed stocks [7]. Recent Developments - The company participated in the 97th WVC Annual Conference from March 3 to 5, 2025, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices, enabling remote image transmission and online diagnostic guidance through its "Mali Doctor" platform [2][3]. Stock Performance - On September 4, 2025, the company's stock price fell by 1.18%, with a trading volume of 84.1682 million yuan and a turnover rate of 5.71%, resulting in a total market capitalization of 10.738 billion yuan [1]. - The average trading cost of the stock is 27.20 yuan, with the current price approaching a resistance level of 25.49 yuan, indicating potential for upward movement if this level is breached [6].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Group 1: Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. - The company has a significant overseas revenue share of 55.26%, benefiting from the depreciation of the RMB [3]. Group 2: Financial Performance - For the period from January to June 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, a year-on-year increase of 18.50% [8]. - The company has distributed a total of 43.69 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On September 1, the company's stock rose by 0.69%, with a trading volume of 95.83 million yuan and a turnover rate of 6.26%, resulting in a total market capitalization of 11.27 billion yuan [1]. - The stock has seen a net outflow of 205,000 yuan from major funds today, with a continuous reduction in major fund holdings over the past three days [4][5].

Core Viewpoint - China Galaxy Securities has reported impressive financial results for the first half of 2025, achieving significant growth in both revenue and net profit, marking a historic high in its 25-year history [2][3]. Financial Performance - The company achieved operating revenue of 13.747 billion yuan, a year-on-year increase of 37.71% [2]. - Net profit attributable to shareholders reached 6.488 billion yuan, up 47.86% year-on-year [2]. - The weighted average return on equity (ROE) was 5.16%, an increase of 1.53 percentage points compared to the same period last year [2]. - Earnings per share rose to 0.52 yuan, reflecting a growth of 36.84% [2]. - Total assets reached 781.74 billion yuan, a growth of 10.24% from the end of the previous year [2]. Business Structure Optimization - The proportion of light capital business has increased significantly, accounting for 46.74% of total revenue, up from 32.36% in 2024 [4]. - Light capital business revenue grew nearly 30% year-on-year, with wealth management, investment banking, and asset management all showing robust growth [4][5]. - Wealth management revenue was 5.926 billion yuan, a 35.55% increase [4]. Wealth Management Growth - The number of domestic clients surpassed 18 million, with nearly 1 million new clients added since the end of 2024 [6]. - The cumulative number of personal pension accounts exceeded 180,000, indicating strong growth in inclusive finance [6]. - Financial product holdings reached 214.147 billion yuan, with a 1.4% increase since the beginning of the year [6]. Digital Transformation - The company is enhancing its digital capabilities, with AI-driven customer service significantly improving efficiency [7]. - The investment advisory team expanded by 313 members, bringing the total to 4,111, enhancing service coverage and expertise [7]. Investment Banking Highlights - The company ranked eighth in equity underwriting with a scale of 20.598 billion yuan and seventh in major asset restructuring transactions at 11.5 billion yuan [8][9]. - Notable projects include assisting the successful domestic listing of a technology innovation company and advising on significant state-owned enterprise restructuring [8]. International Expansion - The international business has shown strong growth, with significant achievements in the Hong Kong market and Southeast Asia [9]. - The company completed 11 IPO projects in Hong Kong and 34 equity and bond financing transactions in Southeast Asia, enhancing its brand influence [9]. Future Outlook - As it celebrates its 25th anniversary, the company aims to continue enhancing its service capabilities and expanding its light capital business [10][11]. - The firm is focused on digital transformation and international market expansion, particularly in Southeast Asia, to strengthen its competitive position [11][12].

Group 1 - The company announced that its second supervisory board meeting approved multiple proposals, including the "2025 Semi-Annual Report" and its summary [2]

Group 1 - The core point of the article is that Chao Yan Co., Ltd. announced the approval of multiple proposals, including the revision of the company's articles of association, during the ninth meeting of its second board of directors [2] Group 2 - The announcement was made on the evening of August 27 [2] - The meeting involved significant corporate governance decisions that may impact the company's operational framework [2] - The specific details of the revised articles of association were not disclosed in the announcement [2]

Core Viewpoint - The company announced the appointment of new senior management personnel to support its operational development needs [1] Group 1: Management Appointments - The company held its second board meeting on August 26, 2025, where it approved the appointment of new senior management [1] - Zheng Yanna and Li Bin were appointed as executive vice presidents, while Li Bohan and Lin Jinhao were appointed as vice presidents [1] - The term for these appointments will last until the end of the current board's term [1]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a focus on the pet economy and smart medical technology [2][3][7]. Group 1: Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025 [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices, and is recognized as a national key high-tech enterprise [7]. Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the number of shareholders decreased by 16.65% to 22,300, while the average circulating shares per person increased by 19.98% to 2,456 shares [8]. - The company has distributed a total of 43.69 million yuan in dividends since its A-share listing [8]. Group 3: Market Dynamics - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. - The company participated in the 97th WVC annual meeting, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and gained valuable insights from industry experts [2]. Group 4: Technical Analysis - The average trading cost of the company's shares is 27.99 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [6]. - The current stock price is near a support level of 26.85 yuan, and if this support is breached, it may trigger a downward trend [6]. Group 5: Investment Sentiment - The stock experienced a decline of 2.68% on August 27, with a trading volume of 206 million yuan and a turnover rate of 12.85%, resulting in a total market capitalization of 11.514 billion yuan [1]. - The main capital flow showed a net outflow of 4.67 million yuan, indicating a reduction in main capital positions over three consecutive days [4][5].